Aptar Pharma, a global leader in drug delivery, dosing, protection technologies and services, announced a collaborative system-level framework for inject...
In a significant move to advance the treatment of patients with inflammatory breast cancer (IBC), Dana-Farber Cancer Institute, The Ohio State Univ...
-Crown Bioscience is a global contract research organization (CRO) specializing in oncology drug discovery and development, today announced it has joined...
GEM Global Yield LLC SCS ("GEM") has executed a Share Purchase Agreement (the "SPA") with the existing shareholders of Taiwan-listed Senhwa Biosciences Inc...
Consortium initially brings together Lunit, Mindpeak, Imagene AI, Dipath AI, Nucleai, Tivenix and Indica Labs to give biopharma sponsors a single CRO-led...
$2 million grant builds on research to develop sequence elements that improve DNA- and RNA-based medicine efficacy Primrose Bio, Inc., a company with pr...
CPC Biotech, part of PSG and Dover (NYSE: DOV) and a leading manufacturer of connectors, pumps, and flow sensors used in biopharmaceu...
As artificial intelligence and advanced technologies transform the pharmaceutical industry, leaders face the challenge of harnessing innovation wit...
Partnership combines large-scale real-world imaging and clinical data with advanced AI capabilities to accelerate biomarker development, real-world evi...
Multi-year program supports development of disposable molecular diagnostic platforms for point-of-care, field-use, and emergency response settings ...
Leica Biosystems, an operating company of Danaher (the "Company"), and a global leader in anatomic pathology solutions advancing precision cancer diagnosti...
Bavarian Nordic A/S (announced that its partner, Eurofarma, has submitted a marketing authorization application to the Brazilian Health Regulatory Agency...
Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced that it has achieved ...
First patient dosed with ZI-MA4-1 in the ZIMA-101 Phase 1 trial at The Christie NHS Foundation Trust ZI-MA4-1 is the world’s first MAGE-A4-targe...
© 2026 Biopharma Boardroom. All Rights Reserved.
